A Weight-Loss Drug Already Approved Overseas: A Chattanooga Physician on Mazdutide
A Weight-Loss Drug Already Approved Overseas: A Chattanooga Physician on Mazdutide
I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. I read every patient chart myself. “Approved somewhere in the world” and “the right choice for you” are two very different statements, and the space between them is where good medicine lives. Mazdutide is a genuinely important drug — and its story quietly makes the case for how I already practice in Tennessee.
What Is Mazdutide?
Mazdutide is a dual agonist — like pemvidutide, it activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 arm curbs appetite; the glucagon arm raises energy expenditure and acts on the liver. It is a once-weekly injection, and it holds a notable distinction: it is the first medication of its GLP-1/glucagon class to win regulatory approval anywhere in the world, cleared by China’s regulator for weight management in June 2025 and for type 2 diabetes later that year (developed by Innovent Biologics with Eli Lilly).
In the United States, though, mazdutide is investigational. It is not FDA-approved, it cannot be prescribed here, and its US trials are still underway. So for a patient in Chattanooga, it is not an option you can fill at a pharmacy today — no matter what you read online.
The Numbers — and the More Important Lesson
The efficacy is real. In the pivotal GLORY-1 trial, the 6 mg dose produced about 14.0 percent average weight loss at 48 weeks, versus roughly no change on placebo (Ji L et al, New England Journal of Medicine 2025, PMID 40421736). A higher-dose trial, GLORY-2, pushed the 9 mg dose to about 16.7 percent average weight loss at 60 weeks (Gao L et al, JAMA 2026, PMID 42251595). Both trials also improved blood pressure, cholesterol, and liver fat. Trial averages, not guarantees — individual results vary.
But here is what I want you to take from those trials, and it is not the percentage. Look at how they got there. The successful arms used careful, stepwise dose escalation — starting low and stepping up over weeks. And when the dose was pushed to the highest level, the side effects rose with it: in the 9 mg trial, more than half of participants had vomiting. The lesson is one I repeat constantly: a bigger dose is not automatically a better outcome. How a drug is titrated — the pace, the adjustments, the attention — often matters more than which drug it is.
What the Mazdutide Story Confirms
Strip away the excitement and mazdutide reinforces the fundamentals of good weight-loss care. The trials that worked did three things: they escalated the dose deliberately, they watched for side effects, and they paired the medication with lifestyle change. None of that is exotic. All of it is available in Tennessee right now, with FDA-approved medications and a physician who is actually paying attention.
What I Do for Patients at Summit Today
At Summit Metabolic Health, I do not need an unapproved import to give patients an excellent outcome. I use the proven, FDA-approved medications we have — and I run them with the same discipline that made the frontier trials succeed.
A drug approved overseas is not your shortcut. A physician who titrates carefully is your real advantage — and you can have that in Chattanooga today.
This is where a physician-led program and a telehealth refill mill genuinely diverge. A mill maximizes the dose to maximize the sale, then leaves you to manage the fallout. I titrate to the lowest effective dose your body tolerates, adjust when side effects appear, and read your labs the whole way. That is not a feature — it is the entire job, and it is why I read every chart at Summit myself.
And because Summit builds an exit strategy into every plan — reach your goal weight, then taper the medication in a controlled way — the aim is durable results rather than an endless prescription. It is also the program designed to get cheaper as you get healthier.
The Bottom Line for Chattanooga
Mazdutide is an important, effective drug — and a preview of the GLP-1/glucagon wave headed toward the US. But it is approved in China, not here, and it is not something to chase across a border. Its real message is the one I have been making all along: careful, physician-led dosing is what turns a good molecule into a good outcome. That is available in Tennessee today, with the medications we already trust.
Want weight-loss care done carefully, by an actual physician? Book a free 20-minute consultation with Dr. Miranda.
You can apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.